aPODD - accelerating Pardiatric Oncology Drug Development Logo

Overview

The discovery and development of new drugs presents huge challenges and risks, even more so for childhood cancers. The relatively small number of patients (compared to adults) does not encourage industry to research and develop specific drugs to fight the types of cancer that commonly affect children.

The only way to get newer, better drugs for children with cancer is to make the drug discovery and development process faster, smoother and less risky for industry and academic partners.

aPODD is a patient-lead group of industrial and scientific experts determined to bridge the gaps that hinder children’s cancer drug development.

We support and run research and development programmes for the testing of potential new therapies to treat childhood cancer and push for their clinical use and marketing approval. All these programmes are run through collaborations with leading academic centres, research organisations and drug makers. aPODD will ensure that funds will be allocated in the most effective way and that all deadlines will be met.

aPODD’s business model is based on “de-risking” drug development by providing scientific/regulatory resources and upfront investment when most needed. In so doing, we create incentives for further development and powerful synergies with industry and academia.

News All News »

More ambitious collaborative models are needed - Open Letter
We often hear from childhood cancer charities calls for deeper and wider collaborations among key stakeholders. I fully agree that collaborations are beneficial but I do feel that we must further...
read more

paediatric oncology facts

Childhood Cancer Statistics

Cancer is the leading cause of death by disease for children in the developed world, Despite undeniable medical progress, achieved through international collaborations within the paediatric oncology community, a great many young cancer patients face a very poor prognosis and too many children continue to die of cancer every year.

read more